Another month, another gliflozin filing in Japan
This article was originally published in Scrip
Executive Summary
Approval submissions for Japan's next class of diabetes drugs, the "gliflozin" sodium-glucose co-transporter 2 (SGLT2) inhibitors, continue to come thick and fast, with Sanofi and Kowa the latest to enter the highly competitive fray with tofogliflozin (CSG452).
You may also be interested in...
Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Asia Deal Watch: Cancer Collaborations, Licensings Lead Activity In Asia
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Atlas, Rise! Japan Cancer Center Builds Asia Trial Network
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.
Need a specific report? 1000+ reports available
Buy Reports